LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Study sponsor: NovoCure GmbH
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-10Estimated
Enrollment · participants734Estimated
Source updated2026-11-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.